Comparative efficacy of three commercial feline leukemia virus vaccines against methylprednisolone acetate-augmented oronasal challenge exposure with virulent virus.
Three commercial FeLV vaccines, (A, B, and C) were purchased on the open market and administered to 8- to 20-week-old specific-pathogen-free kittens, according to manufacturers' instructions. A similar group of nonvaccinated kittens served as controls. All kittens were challenge-exposed oronasally with virulent FeLV 4 weeks after the final vaccination. Serum samples were monitored for FeLV-p27 antigenemia using an ELISA at 1- to 2-week intervals for at least 16 weeks after the last day of challenge exposure. Kittens that were either transiently (1 to 4 weeks) or never viremic during this period were counted as recovered, whereas kittens that became viremic and retained viremia for at least 10 weeks were counted as persistently viremic. The 3 vaccines were found to be 39% (vaccine C), 28% (vaccine B), and 17% (vaccine A) efficacious in preventing persistent viremia in immunized, compared with nonimmunized kittens.
Pedersen
N C
NC
Department of Medicine, School of Veterinary Medicine, University of California, Davis 95616.
Johnson
L
L
D000818:Animals; D000956:Antigens, Viral / Q000097:blood; D002415:Cats; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005256:Leukemia Virus, Feline / Q000276:immunology*; D016582:Leukemia, Feline / Q000517:prevention & control*; D008297:Male; D011897:Random Allocation; D015682:Retroviridae Proteins, Oncogenic; D013047:Specific Pathogen-Free Organisms; D014611:Vaccination / Q000662:veterinary*; D014765:Viral Vaccines; D014766:Viremia / Q000517:prevention & control / Q000662:veterinary*
D000956:Antigens, Viral; D015682:Retroviridae Proteins, Oncogenic; D014765:Viral Vaccines; C045569:feline leukemia virus vaccine